Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso
Hydroxychloroquine
2019-20 coronavirus outbreak
DOI:
10.1016/j.ijid.2022.02.034
Publication Date:
2022-02-26T06:57:27Z
AUTHORS (17)
ABSTRACT
ObjectivesOur study aimed to assess the statistical relationship between use of chloroquine phosphate or hydroxychloroquine plus azithromycin (CQ/HCQ + AZ) and virological recovery, disease worsening, death among out- inpatients with COVID-19 in Burkina Faso.Methods DesignsThis was a retrospective observational that compared outcomes terms time patients who received CQ/HCQ AZ those did not using multivariable Cox Poisson model before after propensity matching.ResultsOf 863 included study, about 50% (432/863) were home-based follow-up inpatients. Of these, 83.3% (746/863) at least 1 dose 13.7% (118/863) not. There no significant differences associated recovery for receiving any (adjusted HR 1.44; 95% CI 0.76–2.71). Similarly, there association worsening IRR 0.80; 0.50–1.50). However, untreated group, treated group had lower risk 0.20; 0.10–0.44).ConclusionsThe provided valuable additional information on show harmful treatment.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (41)
CITATIONS (3)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....